SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Beats Expectations By $0.03 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03, FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is progressing: adult and adolescent cohorts are fully enrolled and closed to screening, and SAB Bio expects to complete enrollment in Q4 2026. Top-line data are expected in the second half of 2027.
• The FDA granted Fast Track designation to SAB-142, which may allow more frequent FDA interactions and rolling review of a future BLA; the designation does not guarantee approval or change the approval standard.
• The investigator-led PRISE study expects to dose its first patient in Q4 2026 and will evaluate SAB-142 in patients diagnosed up to two years earlier. Management sees the study as a potential path to expanding the eligible population, but did not provide a data timeline.
• SAB Bio reported $205 million in cash, cash equivalents and investment securities at quarter-end and said its cash should fund operations through 2028, including the planned PRISE expenses.
• Quarterly R&D and G&A expenses rose to $18.1 million and $7.8 million, respectively, as the company advanced its clinical program; SAB Bio reported a $22.3 million net loss versus net income a year earlier, when results included a large warrant-liability fair-value gain.

SAB Biotherapeutics Trading Down 7.5%

NASDAQ SABS traded down $0.24 on Thursday, hitting $2.94. The company’s stock had a trading volume of 293,144 shares, compared to its average volume of 669,102. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 1-year low of $2.44 and a 1-year high of $5.15. The company’s 50-day moving average is $3.21 and its 200 day moving average is $3.67.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Weiss Ratings upgraded shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 10th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.